MCID: RTN008
MIFTS: 75

Retinitis Pigmentosa malady

Categories: Genetic diseases, Rare diseases, Eye diseases

Aliases & Classifications for Retinitis Pigmentosa

About this section
Sources:
65UMLS, 32LifeMap Discovery®, 10Disease Ontology, 21GeneReviews, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 49OMIM, 67UniProtKB/Swiss-Prot, 36MeSH, 24GTR, 27ICD10, 42NCIt, 59SNOMED-CT, 66UMLS via Orphanet, 28ICD10 via Orphanet, 37MESH via Orphanet, 34MedGen
See all MalaCards sources

Aliases & Descriptions for Retinitis Pigmentosa:

Name: Retinitis Pigmentosa 32 10 21 45 22 23 47 12 51 49 67 36 65
Rp 10 45 23 67
Rod-Cone Dystrophy 45 23 67
Pericentral Pigmentary Retinopathy 10 65
Retinitis Pigmentosa Autosomal Recessive 67
Non-Syndromic Retinitis Pigmentosa 67
Retinitis Pigmentosa Syndrome 24
Retinitis Pigmentosa Type 59 10
Retinitis Pigmentosa Type 53 10
 
Tapetoretinal Degeneration 23
Retinitis Pigmentosa-1 10
Pigmentary Retinopathy 23
Retinitis Pigmentosa 1 65
Cone Rod Dystrophy 51
Rhyns Syndrome 65
Arrp 67
Rcd 67

Characteristics:

Orphanet epidemiological data:

51
retinitis pigmentosa:
Inheritance: Autosomal dominant,Autosomal recessive,Mitochondrial inheritance,X-linked recessive; Prevalence: 1-5/10000 (Europe),1-5/10000 (Worldwide),1-5/10000 (Denmark),1-5/10000 (Norway),1-5/10000 (United States),1-5/10000 (United Kingdom),1-5/10000 (China),1-5/10000 (Slovenia); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy
cone rod dystrophy:
Inheritance: Autosomal dominant,Autosomal recessive,X-linked recessive; Age of onset: Childhood; Age of death: normal life expectancy

Classifications:

Orphanet: 51 
Rare eye diseases


External Ids:

Disease Ontology10 DOID:10584
ICD1027 H35.52
NCIt42 C85045
Orphanet51 791, 1872
SNOMED-CT59 155113002, 28835009
UMLS via Orphanet66 C0035334
ICD10 via Orphanet28 H35.5
MESH via Orphanet37 D012174
MedGen34 C0035334
OMIM49 268000
UMLS65 C0035334, C0220701, C4024782 C1865794, more

Summaries for Retinitis Pigmentosa

About this section
OMIM:49 Retinitis pigmentosa (RP) refers to a heterogeneous group of inherited ocular diseases that result in a progressive... (268000) more...

MalaCards based summary: Retinitis Pigmentosa, also known as rp, is related to rpe65-related retinitis pigmentosa and cortisone reductase deficiency 1, and has symptoms including photophobia, nyctalopia and abnormality of retinal pigmentation. An important gene associated with Retinitis Pigmentosa is CRX (Cone-Rod Homeobox), and among its related pathways are Metabolism of fat-soluble vitamins and Phototransduction. Affiliated tissues include bone, retina and eye, and related mouse phenotypes are vision/eye and nervous system.

Disease Ontology:10 A retinal degeneration characterized by the gradual deterioration of the photoreceptors or the retinal pigment epithelium of the retina leading to progressive sight loss.

NIH Rare Diseases:45 Retinitis pigmentosa (rp) is the name given to a group of inherited eye diseases that affect the light-sensitive part of the eye (retina). rp causes cells in the retina to breakdown and die, eventually resulting in vision loss. the first sign of rp is usually night blindness. as the condition progresses, affected individuals also develop tunnel vision. sometimes rp occurs by itself (isolated rp), and other times it occurs with additional signs and symptoms (syndromic rp). mutations in at least 50 genes have been found to cause rp.  currently, treatment options to slow down the progression of the disease include light avoidance, use of low-vision aids, and vitamin a supplementation. researchers are working to develop new technologies including gene therapy, stem cell transplantation and prosthetic implants. these methods have been studied in animal models, and could potentially preserve and restore vision. last updated: 2/23/2016

UniProtKB/Swiss-Prot:67 Retinitis pigmentosa: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

Genetics Home Reference:23 Retinitis pigmentosa is a group of related eye disorders that cause progressive vision loss. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with retinitis pigmentosa, vision loss occurs as the light-sensing cells of the retina gradually deteriorate.

Wikipedia:68 Retinitis pigmentosa (RP) is an inherited, degenerative eye disease that causes severe vision impairment... more...

GeneReviews summary for NBK1417

Related Diseases for Retinitis Pigmentosa

About this section

Diseases in the Retinitis Pigmentosa family:

Retinitis Pigmentosa 59 Retinitis Pigmentosa 20
Retinitis Pigmentosa 19 Retinitis Pigmentosa 32
Retinitis Pigmentosa 18 Retinitis Pigmentosa 35
Retinitis Pigmentosa-12, Autosomal Recessive Retinitis Pigmentosa 67
Retinitis Pigmentosa 39 Retinitis Pigmentosa 58
Retinitis Pigmentosa 54 Retinitis Pigmentosa 71
Retinitis Pigmentosa 28 Retinitis Pigmentosa 33
Retinitis Pigmentosa 38 Retinitis Pigmentosa 26
Retinitis Pigmentosa 47 Retinitis Pigmentosa 55
Retinitis Pigmentosa 56 Retinitis Pigmentosa 4, Autosomal Dominant or Recessive
Retinitis Pigmentosa 61 Retinitis Pigmentosa 68
Retinitis Pigmentosa-40 Retinitis Pigmentosa 41
Retinitis Pigmentosa 49 Retinitis Pigmentosa 29
Retinitis Pigmentosa 43 Retinitis Pigmentosa 62
Retinitis Pigmentosa 14 Retinitis Pigmentosa 48
Retinitis Pigmentosa 25 Retinitis Pigmentosa 63
Retinitis Pigmentosa 42 Retinitis Pigmentosa 9
Retinitis Pigmentosa 10 Retinitis Pigmentosa 73
Retinitis Pigmentosa 1 Retinitis Pigmentosa 31
Retinitis Pigmentosa 70 Retinitis Pigmentosa 66
Retinitis Pigmentosa 44 Retinitis Pigmentosa 72
Retinitis Pigmentosa-50 Retinitis Pigmentosa 27
Retinitis Pigmentosa 51 Retinitis Pigmentosa 37
Retinitis Pigmentosa 22 Retinitis Pigmentosa 45
Retinitis Pigmentosa 74 Retinitis Pigmentosa 13
Retinitis Pigmentosa 36 Retinitis Pigmentosa 17
Retinitis Pigmentosa 30 Retinitis Pigmentosa 57
Retinitis Pigmentosa 11 Retinitis Pigmentosa 46
Retinitis Pigmentosa 69 Retinitis Pigmentosa 60
Retinitis Pigmentosa 23 Retinitis Pigmentosa 3
Retinitis Pigmentosa 2 Retinitis Pigmentosa 24
Retinitis Pigmentosa 34 Abca4-Related Retinitis Pigmentosa
Aipl1-Related Retinitis Pigmentosa Arl6-Related Retinitis Pigmentosa
Best1-Related Retinitis Pigmentosa C2orf71-Related Retinitis Pigmentosa
C8orf37-Related Retinitis Pigmentosa Ca4-Related Retinitis Pigmentosa
Cerkl-Related Retinitis Pigmentosa Clrn1-Related Retinitis Pigmentosa
Cnga1-Related Retinitis Pigmentosa Cngb1-Related Retinitis Pigmentosa
Crb1-Related Retinitis Pigmentosa Crx-Related Retinitis Pigmentosa
Dhdds-Related Retinitis Pigmentosa Eys-Related Retinitis Pigmentosa
Fam161a-Related Retinitis Pigmentosa Fscn2-Related Retinitis Pigmentosa
Guca1b-Related Retinitis Pigmentosa Idh3b-Related Retinitis Pigmentosa
Impdh1-Related Retinitis Pigmentosa Impg2-Related Retinitis Pigmentosa
Klhl7-Related Retinitis Pigmentosa Lrat-Related Retinitis Pigmentosa
Mak-Related Retinitis Pigmentosa Mertk-Related Retinitis Pigmentosa
Nr2e3-Related Retinitis Pigmentosa Nrl-Related Retinitis Pigmentosa
Pde6a-Related Retinitis Pigmentosa Pde6b-Related Retinitis Pigmentosa
Pde6g-Related Retinitis Pigmentosa Prcd-Related Retinitis Pigmentosa
Prom1-Related Retinitis Pigmentosa Prpf3-Related Retinitis Pigmentosa
Prpf31-Related Retinitis Pigmentosa Prpf6-Related Retinitis Pigmentosa
Prpf8-Related Retinitis Pigmentosa Prph2-Related Retinitis Pigmentosa
Rbp3-Related Retinitis Pigmentosa Rdh12-Related Retinitis Pigmentosa
Rgr-Related Retinitis Pigmentosa Rho-Related Retinitis Pigmentosa
Rom1-Related Retinitis Pigmentosa Rp1-Related Retinitis Pigmentosa
Rp2-Related Retinitis Pigmentosa Rp9-Related Retinitis Pigmentosa
Rpe65-Related Retinitis Pigmentosa Rpgr-Related Retinitis Pigmentosa
Sag-Related Retinitis Pigmentosa Sema4a-Related Retinitis Pigmentosa
Snrnp200-Related Retinitis Pigmentosa Spata7-Related Retinitis Pigmentosa
Topors-Related Retinitis Pigmentosa Ttc8-Related Retinitis Pigmentosa
Tulp1-Related Retinitis Pigmentosa Ush2a-Related Retinitis Pigmentosa
Znf513-Related Retinitis Pigmentosa

Diseases related to Retinitis Pigmentosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 937)
idRelated DiseaseScoreTop Affiliating Genes
1rpe65-related retinitis pigmentosa34.6CRX, RPE65
2cortisone reductase deficiency 133.1RPE65, USH2A
3leukemia32.4ABCA4, BEST1, CRB1, CRX, IFT140, PDE6B
4exudative vitreoretinopathy31.4ABCA4, PDE6B, RHO, RPE65, RPGR
5lung disease31.2PDE6B, RHO, RPE65
6newfoundland rod-cone dystrophy12.9
7retinitis pigmentosa 312.6
8retinitis pigmentosa 7 and digenic12.6
9neuropathy ataxia retinitis pigmentosa syndrome12.6
10ataxia, posterior column, with retinitis pigmentosa12.6
11retinitis pigmentosa 212.6
12retinitis pigmentosa 1412.6
13polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract12.6
14retinitis pigmentosa 1112.5
15retinitis pigmentosa 2012.5
16retinitis pigmentosa 1912.5
17retinitis pigmentosa 1812.5
18retinitis pigmentosa 3512.5
19retinitis pigmentosa 2812.5
20retinitis pigmentosa 3312.5
21retinitis pigmentosa 2612.5
22retinitis pigmentosa 4, autosomal dominant or recessive12.5
23retinitis pigmentosa 4112.5
24retinitis pigmentosa 2512.5
25retinitis pigmentosa 112.5
26retinitis pigmentosa 3112.5
27retinitis pigmentosa 1312.5
28retinitis pigmentosa 3612.5
29retinitis pigmentosa 1712.5
30retinitis pigmentosa 3012.5
31retinitis pigmentosa 4612.5
32retinitis pigmentosa, x-linked, and sinorespiratory infections, with or without deafness12.5
33cerebellar hypoplasia tapetoretinal degeneration12.5
34retinitis pigmentosa 3812.5
35retinitis pigmentosa 912.5
36retinitis pigmentosa 5912.5
37retinitis pigmentosa 3912.5
38retinitis pigmentosa 5812.5
39retinitis pigmentosa 5412.5
40retinitis pigmentosa 4712.5
41retinitis pigmentosa 5512.5
42retinitis pigmentosa 6112.5
43retinitis pigmentosa 4912.5
44retinitis pigmentosa 4312.5
45retinitis pigmentosa 6212.5
46retinitis pigmentosa 4812.5
47retinitis pigmentosa 4212.5
48retinitis pigmentosa 1012.5
49retinitis pigmentosa 4412.5
50retinitis pigmentosa 2712.5

Graphical network of the top 20 diseases related to Retinitis Pigmentosa:



Diseases related to retinitis pigmentosa

Symptoms for Retinitis Pigmentosa

About this section

Symptoms by clinical synopsis from OMIM:

268000

Clinical features from OMIM:

268000

Symptoms:

 51 (show all 30)
  • retinal vascular anomalies/retinal telangiectasia
  • retinitis pigmentosa/retinal pigmentary changes
  • optic nerve anomaly/optic atrophy/anomaly of the papilla
  • visual loss/blindness/amblyopia
  • night blindness/hemeralopia
  • mild visual loss/impaired visual acuity
  • photophobia
  • abnormal erg/electroretinogram/electroretinography
  • nystagmus
  • broad nasal root
  • anteverted nares/nostrils
  • sensorineural deafness/hearing loss
  • conductive deafness/hearing loss
  • abnormal scarring/cheloids/hypertrophic scars
  • micropenis/small penis/agenesis
  • small/atrophic/hypoplastic testes/monorchism/microorchidism/anorchia
  • late puberty/hypogonadism/hypogenitalism
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • autosomal dominant inheritance
  • autosomal recessive inheritance
  • x-linked recessive inheritance
  • glaucoma
  • keratoconus/keratoglobus
  • cataract/lens opacification
  • ophthalmoplegia/ophthalmoparesis/oculomotor palsy
  • hyperinsulinism/hyperinsulinemia
  • generalized obesity
  • insulin-independent/type 2 diabetes
  • hypereflexia
  • achromatopsia/dyschromatopsia/daltonism/impaired colour vision

HPO human phenotypes related to Retinitis Pigmentosa:

(show all 29)
id Description Frequency HPO Source Accession
1 photophobia hallmark (90%) HP:0000613
2 nyctalopia hallmark (90%) HP:0000662
3 abnormality of retinal pigmentation hallmark (90%) HP:0007703
4 abnormality of the testis hallmark (90%) HP:0000035
5 conductive hearing impairment hallmark (90%) HP:0000405
6 sensorineural hearing impairment hallmark (90%) HP:0000407
7 wide nasal bridge hallmark (90%) HP:0000431
8 anteverted nares hallmark (90%) HP:0000463
9 visual impairment hallmark (90%) HP:0000505
10 abnormal electroretinogram hallmark (90%) HP:0000512
11 nystagmus hallmark (90%) HP:0000639
12 optic atrophy hallmark (90%) HP:0000648
13 atypical scarring of skin hallmark (90%) HP:0000987
14 abnormality of the retinal vasculature hallmark (90%) HP:0008046
15 hypoplasia of penis hallmark (90%) HP:0008736
16 cognitive impairment hallmark (90%) HP:0100543
17 abnormality of color vision typical (50%) HP:0000551
18 glaucoma typical (50%) HP:0000501
19 cataract typical (50%) HP:0000518
20 ophthalmoparesis typical (50%) HP:0000597
21 hyperinsulinemia typical (50%) HP:0000842
22 obesity typical (50%) HP:0001513
23 decreased corneal thickness typical (50%) HP:0100689
24 visual impairment occasional (7.5%) HP:0000505
25 hyperreflexia occasional (7.5%) HP:0001347
26 type ii diabetes mellitus occasional (7.5%) HP:0005978
27 constriction of peripheral visual field HP:0001133
28 nyctalopia HP:0000662
29 rod-cone dystrophy HP:0000510

Drugs & Therapeutics for Retinitis Pigmentosa

About this section

Drugs for Retinitis Pigmentosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 98)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Phosphodiesterase InhibitorsPhase 41062
2Phosphodiesterase 5 InhibitorsPhase 4513
3Vasodilator AgentsPhase 42926
4Sildenafil CitratePhase 4304171599-83-0
5CitrateNutraceuticalPhase 41001
6
Citric AcidnutraceuticalPhase 4100177-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
7
Vitamin Aapproved, nutraceuticalPhase 3, Phase 141311103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(2e,4e,6e,8e)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Chocola a
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A palmitate
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin a
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
8
Luteinapproved, nutraceuticalPhase 3, Phase 1, Phase 269127-40-25368396, 6433159
Synonyms:
(3R,3'R)-beta,beta-Carotene-3,3'-Diol, Lutein
(3R,3'R,6'R)-Lutein
(3R,3'R,6S)-4,5-Didehydro-5,6-Dihydro-beta,beta-Carotene-3,3'-Diol
3,3'-Dihydroxy-alpha-carotene
4,5-Didehydro-5,6-dihydro-beta,beta-carotene-3,3'-diol
All-trans-(+)-Xanthophyll
All-trans-Lutein
All-trans-Xanthophyll
 
Bo-Xan
Lutein
Lutein ester
Luteine
Phylloxanthin
SID548587
Vegetable lutein
Vegetable luteol
beta,epsilon-Carotene-3,3'-diol
trans-Lutein
9
Vitamin Eapproved, nutraceuticalPhase 337159-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-alpha-tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-ol
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'r)-alpha-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-alpha-tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitamin e
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
d-alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
10VitaminsPhase 3, Phase 2, Phase 1, Phase 03857
11Antihypertensive AgentsPhase 3, Phase 1, Phase 23618
12TocotrienolsPhase 3372
13vitamin dPhase 31524
14TocopherolsPhase 3376
15Trace ElementsPhase 3, Phase 2, Phase 1, Phase 03900
16Protective AgentsPhase 3, Phase 2, Phase 15651
17Retinol palmitatePhase 3, Phase 1413
18AntioxidantsPhase 3, Phase 2, Phase 12442
19MicronutrientsPhase 3, Phase 2, Phase 1, Phase 03901
20CarotenoidsPhase 2, Phase 3, Phase 1119
21Isopropyl unoprostonePhase 32
22TocopherolNutraceuticalPhase 3376
23TocotrienolNutraceuticalPhase 3372
24retinolNutraceuticalPhase 3, Phase 1413
25Beta CaroteneNutraceuticalPhase 2, Phase 3, Phase 161
26
Valproic Acidapproved, investigationalPhase 231199-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-PROPYL-pentanoic acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Depakote ER
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VALPROIC acid
VPA
Valcote
Valparin
Valproate
Valproate Semisodium
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic
Valproic Acid
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
27
Ciprofloxacinapproved, investigationalPhase 2, Phase 121285721-33-12764
Synonyms:
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
17850_FLUKA
3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)
33434_FLUKA
33434_RIEDEL
85721-33-1
AC-7613
AC1L1EEW
AKOS000269653
ARONIS020379
Alcon Cilox
BAS 06989041
BAY q 3939
BAY-Q-3939
BAYQ3939
BIDD:GT0205
BPBio1_000140
BRD-K04804440-311-02-3
BRN 3568352
BSPBio_000126
BSPBio_003344
Bacquinor
Baflox
Bay o 9867
Bay o 9867 (*Hydrochloride*)
Bay-09867
Baycip
Bernoflox
Bi-Cipro
Bio-0540
C05349
C17H18FN3O3
CAS-93107-08-5
CBMicro_048498
CCRIS 5241
CHEBI:100241
CHEMBL8
CID2764
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
CPF
CPFX
CRL-1605 & Ciprofloxacin
Ciflox
Cifloxin
Cilab
Ciloxan
Ciloxan (*Hydrochloride*)
Ciplus
Ciprecu
Ciprinol
Cipro
Cipro (*Hydrochloride*)
Cipro (TN)
Cipro I.V.
Cipro IV
Cipro XL
Cipro XR
Ciprobay
Ciprobay Uro
Ciprocinol
Ciprodar
Ciproflox
Ciprofloxacin
Ciprofloxacin (JAN/USP/INN)
Ciprofloxacin Extended-Release
Ciprofloxacin HCl
Ciprofloxacin Hydrchloride
Ciprofloxacin Hydrochloride
Ciprofloxacin Otic
Ciprofloxacin [USAN:INN:BAN]
Ciprofloxacin dihydrochloride
Ciprofloxacin hydrochloride
Ciprofloxacin monohydrochloride
Ciprofloxacina
Ciprofloxacine
Ciprofloxacine [INN-French]
 
Ciprofloxacino
Ciprofloxacino [INN-Spanish]
Ciprofloxacinum
Ciprofloxacinum [INN-Latin]
Ciprogis
Ciprolin
Ciprolon
Cipromycin
Ciproquinol
Ciprowin
Ciproxan
Ciproxin
Ciproxina
Ciproxine
Ciriax
Citopcin
Cixan
Corsacin
Cycin
Cyprobay
D00186
DB00537
DivK1c_000095
Eni
Fimoflox
Flociprin
Floxin
HMS1922E18
HMS2090O07
HMS2093I03
HMS500E17
HSDB 6987
IDI1_000095
Ipiflox
Italnik
KBio1_000095
KBio2_000642
KBio2_003210
KBio2_005778
KBio3_002846
KBioGR_001567
KBioSS_000642
LS-141563
Liposomal-ciprofloxacin
Loxan
MLS001336035
MolPort-000-819-654
NCGC00016959-01
NCGC00095058-01
NCGC00095058-02
NCGC00178128-01
NINDS_000095
NSC620634
Ocuflox
Oprea1_008239
Oprea1_313572
Prestwick0_000113
Prestwick1_000113
Prestwick2_000113
Prestwick3_000113
Probiox
Proflaxin
Proflox
Proksi 250
Proksi 500
Proquin XR
Quinolid
Quintor
Rancif
Roxytal
SMP1_000125
SMR000471901
SPBio_001474
SPBio_002065
SPECTRUM1503614
STK021082
Septicide
Sophixin Ofteno
Spectrum2_001567
Spectrum3_001872
Spectrum4_000874
Spectrum5_001089
Spectrum_000162
Spitacin
Superocin
UNII-5E8K9I0O4U
Unex
Velomonit
Zumaflox
ciprofloxacin
nchembio820-comp1
28
BleomycinapprovedPhase 214411056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
29
CarboplatinapprovedPhase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
30
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
31
SuccinylcholineapprovedPhase 2141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
32
EtoposideapprovedPhase 2116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
33
CisplatinapprovedPhase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
34
AdapaleneapprovedPhase 1, Phase 271106685-40-960164
Synonyms:
106685-40-9
6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
AC-1974
AC1L1SOH
AC1Q5USH
ADAPALENE
AKOS005145841
Adaferin
Adapalene
Adapalene (JAN/USAN/INN)
Adapalene [USAN:BAN:INN]
Adapaleno
Adapaleno [INN-Spanish]
Adapalenum
Adapalenum [INN-Latin]
Ambap106685-40-9
BIDD:GT0264
C28H28O3
CD 271
CD-271
 
CD271
CHEBI:217732
CHEBI:31174
CHEMBL1265
CHEMBL76401
CID60164
CPD000466349
D01112
DB00210
Differin
Differin (TN)
Differin, Adapalene
Differine
I06-0642
KS-1196
LS-172017
MLS000759463
MolPort-003-986-211
MolPort-006-823-940
NCGC00164617-01
S1276_Selleck
SAM001246663
SMR000466349
TL8000241
UNII-1L4806J2QF
35
EphedrineapprovedPhase 1, Phase 2447299-42-39294
Synonyms:
( )-Pseudoephedrine
(+)-Ephedrin
(+)-Ephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(+-)-Ephedrine
(-)-Ephedrine
(-)-Pseudoephedrine
(-)-psi-Ephedrine
(-)-threo-Ephedrine
(1R,2R)-Ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2R)-Ephedrine
(L)-EPHEDRINE
--EPHEDRINE
1-EPHEDRINE
1-Sedrin
134910_ALDRICH
287636_ALDRICH
287644_ALDRICH
299-42-3
304-87-0
30987-59-8
321-96-0
321-97-1
321-98-2
37577-31-4
38732-95-5
45261_FLUKA
4607-45-8
50-98-6
50906-05-3
53214-57-6
649031_ALDRICH
6912-63-6
7009-81-6
90-82-4
968-63-8
AC-20231
AC-20292
AC1L1JGK
AC1L1NUA
AC1L1RFA
AC1L1SR1
AC1L1T31
AC1L1Y3M
AC1O8JUO
AC1Q3XJE
AC1Q3XJM
AC1Q3XJN
AC1Q59F5
AC1Q7701
AI3-02761
AKOS000268842
AR-1A0126
AR-1I7143
Acunaso
Acunaso (TN)
Afrinol
Ambap299-42-3
BIDD:GT0817
BRN 3197916
BRN 4231286
BSPBio_001946
BSPBio_001968
BSPBio_003261
Benylin Decongestant
Besan
Biophedrin
C01575
C02765
C10H15NO
CHEBI:15407
CHEBI:51209
CHEMBL1590
CHEMBL211456
CHEMBL357080
CID11972440
CID5032
CID62946
CID6710657
CID7028
CID8650
CID9294
CID9457
CPD-9954
CPDD 0049
Cenafed
D00124
D08449
DB00852
DB01364
Decofed
DivK1c_000181
DivK1c_000451
DivK1c_000461
Drixoral N.D.
EINECS 202-017-0
EINECS 202-018-6
EINECS 206-080-5
EINECS 206-292-8
EINECS 206-293-3
Eciphin
Efedrin
Efidac/24
Eltor 120
Ephedral
Ephedremal
Ephedrin
Ephedrine
Ephedrine (TN)
Ephedrine (USP)
Ephedrine [USAN:BAN]
Ephedrine l-form
Ephedrital
Ephedrol
Ephedrosan
Ephedrotal
Ephedsol
Ephendronal
Ephoxamin
Fedrin
Genaphed
HSDB 3072
HSDB 3177
I-Sedrin
I01-3584
I01-8925
I01-8928
 
IDI1_000181
IDI1_000451
IDI1_000461
Isoephedrine
Jsp005664
KBio1_000181
KBio1_000451
KBio1_000461
KBio2_001358
KBio2_001500
KBio2_003926
KBio2_004068
KBio2_006494
KBio2_006636
KBio3_001188
KBio3_001446
KBio3_002762
KBioGR_001013
KBioGR_001763
KBioSS_001358
KBioSS_001500
KST-1A9168
Kratedyn
L(+)-psi-Ephedrine
L(-)-Ephedrine
L-(+)-Ephedrine
L-(-)-Ephedrine
L-Ephedrine
L-erythro-2-(Methylamino)-1-phenylpropan-1-ol
L000968
LS-125921
LS-125922
LS-43083
LS-63961
LS-63962
LS-63963
LS-63964
Lexofedrin
Lopac-E-3250
Lopac0_000501
MLS000069657
Manadrin
Mandrin
Maxenal
MolPort-001-684-474
MolPort-001-684-477
MolPort-001-684-478
MolPort-001-684-479
MolPort-001-769-085
Myfedrine
NCGC00015408-01
NCGC00015408-02
NCGC00162174-01
NCGC00178180-01
NCGC00178889-01
NCI-C55652
NCI60_002955
NINDS_000181
NINDS_000451
NINDS_000461
NSC 165609
NSC 170951
NSC 8971
NSC165609
NSC170951
NSC8971
Nasol
Neodurasina
Neodurasina (TN)
Oprea1_287330
PDSP1_000168
PDSP1_001106
PDSP1_001343
PDSP1_001345
PDSP1_001346
PDSP1_001347
PDSP2_000167
PDSP2_001090
PDSP2_001327
PDSP2_001329
PDSP2_001330
PDSP2_001331
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoephedrine (D)
Pseudoephedrinum
Psi-ephedrin
Psi-ephedrine
Robidrine
SMR000059174
SPBio_000214
SPBio_001365
SPBio_001377
ST023802
STK367993
STOCK1N-42675
Sanedrine
Spectrum2_000137
Spectrum2_001303
Spectrum2_001309
Spectrum3_000414
Spectrum3_000563
Spectrum3_001771
Spectrum4_000497
Spectrum4_001162
Spectrum5_000650
Spectrum5_000879
Spectrum5_001106
Spectrum_000878
Spectrum_001020
Sudafed
Sudafed Decongestant
UNII-03VRY66076
UNII-7CUC9DDI9F
UNII-GN83C131XS
Vencipon
WLN: QYR & Y1 & M1
WLN: QYR&Y1&M1
Zephrol
d-Ephedrine
d-Isoephedrine
d-Pseudoephedrine
d-psi-Ephedrine
l-Ephedrine
l-Pseudoephedrine
racephedrine
trans-Ephedrine
36
Minocyclineapproved, investigationalPhase 1, Phase 217310118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
HMS2090D03
HSDB 3130
LMPK07000002
 
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline
Minocycline (USAN/INN)
Minocycline Hydrochloride
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
Ximino
minociclinum
minocycline
nchembio.559-comp1
37
PseudoephedrineapprovedPhase 1, Phase 244790-82-47028
Synonyms:
( )-Pseudoephedrine
(+)-(1S,2S)-Pseudoephedrine
(+)-Pseudoephedrine
(+)-Psi-ephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
(1S,2S)-2-Methylamino-1-phenyl-1-propanol
(1S,2S)-Pseudoephedrine
(1S,2S)-Pseudoephedrine, polymer-bound
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
287636_ALDRICH
304-87-0
30987-59-8
37577-31-4
649031_ALDRICH
90-82-4
AC-20292
AC1L1NUA
Acunaso
Acunaso (TN)
Afrinol
BIDD:GT0817
BRD-K84175871-003-02-2
BSPBio_003261
Balminil Decongestant Syrup
Benylin Decongestant
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI)
Besan
C02765
C10H15NO
CHEBI:51209
CHEMBL1590
CID7028
CPD-9954
Cenafed
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-Methylamino-1-phenyl-1-propanol
D-Psi-2-methylamino-1-phenyl-1-propanol
D-Psi-Ephedrine
D-Psi-ephedrine
D08449
DB00852
Decofed
Dimetapp Decongestant
Dimetapp Decongestant Pediatric Drops
DivK1c_000451
Drixoral N.D.
Drixoral Nasal Decongestant
EINECS 202-018-6
Efidac 24 Pseudoephedrine Hcl
Efidac/24
Eltor 120
Ephed 60
Ephedrine
Genaphed
HSDB 3177
I01-8928
IDI1_000451
Isoephedrine
KBio1_000451
 
KBio2_001358
KBio2_003926
KBio2_006494
KBio3_002762
KBioGR_001763
KBioSS_001358
L(+)-Psi-Ephedrine
L(+)-Psi-ephedrine
L(+)-psi-Ephedrine
L-(+)-Pseudoephedrine
LS-125922
Lopac-E-3250
Maxenal
MolPort-001-684-474
Myfedrine
NCGC00015408-01
NCGC00178180-01
NCI60_002955
NINDS_000451
Neodurasina
Neodurasina (TN)
Novafed
PDSP1_001347
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoefedrina [INN-Spanish]
Pseudoephedrine
Pseudoephedrine (D)
Pseudoephedrine (INN)
Pseudoephedrine D-form
Pseudoephedrine Ephedrine
Pseudoephedrine Hydrochloride
Pseudoephedrine [INN:BAN]
Pseudoephedrine d-form
Pseudoephedrine hydrochloride
Pseudoephedrine sulfate
Pseudoephedrinum
Pseudoephedrinum [INN-Latin]
Psi-ephedrin
Psi-ephedrine
Robidrine
SPBio_001365
STOCK1N-42675
Spectrum2_001303
Spectrum3_001771
Spectrum4_001162
Spectrum5_000650
Spectrum_000878
Sudafed
Sudafed Decongestant
Sudafed Decongestant 12 Hour
Sudafed Decongestant Extra Strength
Suphedrine
Triaminic AM Decongestant Formula
Triaminic Infant Oral Decongestant Drops
UNII-7CUC9DDI9F
alpha-(1-(Methylamino)ethyl)benzyl alcohol
d-Isoephedrine
d-Pseudoephedrine
d-psi-2-Methylamino-1-phenyl-1-propanol
d-psi-Ephedrine
trans-Ephedrine
38Antimanic AgentsPhase 2663
39AnticonvulsantsPhase 22249
40ProxymetacainePhase 2, Phase 133
41cadexomer iodinePhase 2, Phase 1456
42Povidone-IodinePhase 2, Phase 1134
43Neurotransmitter AgentsPhase 2, Phase 114795
44PovidonePhase 2, Phase 1129
45
IodinePhase 2, Phase 14947553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
46Adrenergic alpha-AgonistsPhase 1, Phase 21300
47Central Nervous System DepressantsPhase 210016
48Tranquilizing AgentsPhase 23597
49Psychotropic DrugsPhase 25501
50Adrenergic AgentsPhase 1, Phase 24204

Interventional clinical trials:

(show top 50)    (show all 119)
idNameStatusNCT IDPhase
1The Role of Capsular Tension Ring (CTR) in Anterior Capsular ContractionCompletedNCT00717080Phase 4
2A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile DysfunctionCompletedNCT00654082Phase 4
3Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin ACompletedNCT00346333Phase 3
4A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaCompletedNCT00447993Phase 2, Phase 3
5A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaCompletedNCT00447980Phase 2, Phase 3
6Randomized Trial for Retinitis PigmentosaCompletedNCT00000116Phase 3
7Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis PigmentosaCompletedNCT00000114Phase 3
8The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella BardawilRecruitingNCT01680510Phase 2, Phase 3
9Retraining Walking After Spinal Cord InjuryActive, not recruitingNCT00059553Phase 2, Phase 3
10Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaTerminatedNCT01786395Phase 3
11Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaCompletedNCT01560715Phase 2
12Safety Study in Retinal Transplantation for Retinitis Pigmentosa.CompletedNCT00345917Phase 2
13Trial of Oral Valproic Acid for Retinitis PigmentosaCompletedNCT01233609Phase 2
14Effects of Lutein in Retinitis PigmentosaCompletedNCT00029289Phase 1, Phase 2
15DHA and X-Linked Retinitis PigmentosaCompletedNCT00100230Phase 2
16Efficacy and Safety of Oral Valproic Acid for Retinitis PigmentosaCompletedNCT01399515Phase 2
17An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis PigmentosaCompletedNCT00661479Phase 1, Phase 2
18Feasibility Study of a Chronic Retinal Stimulator in Retinitis PigmentosaCompletedNCT00279500Phase 1, Phase 2
19Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord InjuryCompletedNCT01321333Phase 1, Phase 2
20Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) StudyRecruitingNCT02661711Phase 2
21Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium BarbarumRecruitingNCT02244996Phase 2
22Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis PigmentosaRecruitingNCT01914913Phase 1, Phase 2
23Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaRecruitingNCT01530659Phase 2
24Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BRecruitingNCT01505062Phase 1, Phase 2
25RST-001 Phase I/II Trial for Retinitis PigmentosaRecruitingNCT02556736Phase 1, Phase 2
26Safety and Tolerability of hRPC in Retinitis PigmentosaRecruitingNCT02464436Phase 1, Phase 2
27Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis PigmentosaRecruitingNCT02320812Phase 1, Phase 2
28Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis PigmentosaRecruitingNCT02709876Phase 1, Phase 2
29Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)RecruitingNCT02338973Phase 1, Phase 2
30Dose Escalation Study of AST-OPC1 in Spinal Cord InjuryRecruitingNCT02302157Phase 1, Phase 2
31Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal TumorsRecruitingNCT01042522Phase 2
32Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström SyndromeRecruitingNCT02739217Phase 2
33Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for the Treatment of Vision Loss Due to Retinitis PigmentosaActive, not recruitingNCT02086890Phase 1, Phase 2
34A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)Active, not recruitingNCT02110225Phase 1, Phase 2
35Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis PigmentosaActive, not recruitingNCT02140164Phase 1, Phase 2
36Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaActive, not recruitingNCT02609165Phase 2
37Argus® II Retinal Stimulation System Feasibility ProtocolActive, not recruitingNCT00407602Phase 2
38Gene Therapy for Blindness Caused by ChoroideremiaActive, not recruitingNCT01461213Phase 1, Phase 2
39Surgical Management of Spinal Cord Injuries In NeckActive, not recruitingNCT00475748Phase 2
40A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1BEnrolling by invitationNCT02065011Phase 1, Phase 2
41The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis PigmentosaNot yet recruitingNCT02018692Phase 1, Phase 2
42Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaCompletedNCT01068561Phase 1
43Acupuncture for the Treatment of Vision Loss Due to Retinitis PigmentosaCompletedNCT01604356Phase 1
44Investigating the Effect of Vitamin A Supplementation on Retinitis PigmentosaCompletedNCT00065455Phase 1
45Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the EyeCompletedNCT00063765Phase 1
46Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)CompletedNCT01543906Phase 1
47Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)CompletedNCT01521793Phase 1
48Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) MutationsCompletedNCT01014052Phase 1
49Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis PigmentosaRecruitingNCT02280135Phase 1
50Retinal Imaging in Patients With Inherited Retinal DegenerationsRecruitingNCT00254605Phase 1

Search NIH Clinical Center for Retinitis Pigmentosa

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinitis Pigmentosa cell therapies at LifeMap Discovery.

Genetic Tests for Retinitis Pigmentosa

About this section

Genetic tests related to Retinitis Pigmentosa:

id Genetic test Affiliating Genes
1 Retinitis Pigmentosa22 ZNF513

Anatomical Context for Retinitis Pigmentosa

About this section

MalaCards organs/tissues related to Retinitis Pigmentosa:

33
Bone, Retina, Eye, Spinal cord, Lung, Breast, Endothelial

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Retinitis Pigmentosa:
id TissueAnatomical CompartmentCell Relevance
1 EyeOuter Nuclear LayerCone Precursor Cells Potential therapeutic candidate, affected by disease
2 EyeOuter Nuclear LayerMature L Cone Cells Potential therapeutic candidate, affected by disease
3 EyeOuter Nuclear LayerMature M Cone Cells Potential therapeutic candidate, affected by disease
4 EyeOuter Nuclear LayerMature M-S Cone Cells Potential therapeutic candidate, affected by disease
5 EyeRetinal Pigmented EpitheliumMature Retinal Pigmented Epithelium Cells Potential therapeutic candidate, affected by disease
6 EyeOuter Nuclear LayerMature Rod Cells Potential therapeutic candidate, affected by disease
7 EyeOuter Nuclear LayerMature S Cone Cells Potential therapeutic candidate, affected by disease
8 EyeRetinal Pigmented EpitheliumRetinal Pigmented Epithelium Progenitor Cells Potential therapeutic candidate, affected by disease
9 EyeOuter Nuclear LayerRod Precursor Cells Potential therapeutic candidate, affected by disease

Animal Models for Retinitis Pigmentosa or affiliated genes

About this section

MGI Mouse Phenotypes related to Retinitis Pigmentosa:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539112.0ABCA4, BEST1, C2orf71, CRB1, CRX, IFT140
2MP:000363111.8ABCA4, C2orf71, CRB1, CRX, IFT140, PDE6B
3MP:000118611.6ABCA4, BEST1, C2orf71, CRB1, CRX, PDE6B
4MP:000538511.3ABCA4, CRX, IFT140, PDE6B, PRPH2, RHO

Publications for Retinitis Pigmentosa

About this section

Articles related to Retinitis Pigmentosa:

(show top 50)    (show all 1287)
idTitleAuthorsYear
1
Flax lignan concentrate reverses alterations in blood pressure, left ventricular functions, lipid profile and antioxidant status in DOCA-salt induced renal hypertension in rats. (26795298)
2016
2
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma. (25927939)
2015
3
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (25037629)
2014
4
Increased expression of oncogene-induced senescence markers during cervical squamous cell cancer development. (25674264)
2014
5
The relationship between MAOA gene polymorphism and test anxiety. (24229476)
2013
6
Rifaximin plus fibre versus fibre alone in preventing diverticulitis recurrence: a (problematic) trial to tackle an epidemiologically relevant problem. (23298762)
2013
7
Morphine is associated with acute chest syndrome in children hospitalized with sickle cell disease. (24340416)
2013
8
Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells. (23453006)
2013
9
Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1. (22079347)
2012
10
Response to DNA damage of CHEK2 missense mutations in familial breast cancer. (22419737)
2012
11
Recovering the personal identity of an elderly patient with cleft lip: a case report. (22943775)
2012
12
Countering hepatitis B virus infection using RNAi: how far are we from the clinic? (21913277)
2011
13
Graded classification of fetal heart rate tracings: association with neonatal metabolic acidosis and neurologic morbidity. (19716539)
2010
14
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. (20015976)
2010
15
Maggot excretions/secretions induces human microvascular endothelial cell migration through AKT1. (19757167)
2010
16
Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. (20347426)
2010
17
C-reactive protein estimation does not improve accuracy in the diagnosis of acute appendicitis in pediatric patients. (19070557)
2009
18
Mechanobiology of the skeleton. (19401590)
2009
19
Crude extracts of Solanum lyratum protect endothelial cells against oxidized low-density lipoprotein-induced injury by direct antioxidant action. (19703745)
2009
20
Effect of renal denervation on prenatal programming of hypertension and renal tubular transporter abundance. (18400872)
2008
21
Translationally regulated C/EBP beta isoform expression upregulates metastatic genes in hormone-independent prostate cancer cells. (18512730)
2008
22
Phytoestrogens and breast cancer: a complex story. (18815740)
2008
23
Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. (17692748)
2007
24
Prevalences of oligozoospermia and azoospermia in male partners of infertile couples from different parts of India. (16372124)
2006
25
Atypical teratoid/rhabdoid tumor of the spinal canal. (16411024)
2006
26
In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. (16953186)
2006
27
Is patient's age a prognostic factor for follicular thyroid carcinoma in the TNM classification system? (15929665)
2005
28
Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. (14965340)
2004
29
Homeodomain-leucine zipper proteins interact with a plant homologue of the transcriptional co-activator multiprotein bridging factor 1. (15469713)
2004
30
Carnitine prevents cyclic GMP-induced inhibition of peroxisomal enzyme activities. (15386443)
2004
31
N-linked glycosylation of the human bradykinin B2 receptor is required for optimal cell-surface expression and coupling. (14977046)
2004
32
Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. (12717734)
2003
33
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. (12874026)
2003
34
Childhood Brain Stem Glioma Treatment (PDQAr): Health Professional Version (27010061)
2002
35
Pontine atrophy in spinocerebellar ataxia type 6. (10601803)
2000
36
Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. (11082413)
2000
37
The DNA binding domain of the human c-Abl tyrosine kinase preferentially binds to DNA sequences containing an AAC motif and to distorted DNA structures. (9558345)
1998
38
Surgical management of pulmonary aspergilloma. (9371201)
1997
39
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. (7518346)
1994
40
Cytokines and eosinophil-derived cationic proteins upregulate intercellular adhesion molecule-1 on human nasal epithelial cells. (8104967)
1993
41
Classical genetic analyses of responses to sedative-hypnotic drugs in crosses derived from long-sleep and short-sleep mice. (1352660)
1992
42
"Solitary" rectal ulcer syndrome. Are "solitary" rectal ulcer syndrome and "localized" colitis cystica profunda analogous syndromes caused by rectal prolapse? (3536653)
1987
43
Bernard-Soulier syndrome presenting as recurrent exsanguinating haematemesis. (3699856)
1986
44
Causalgia: a review of 48 cases. (13223107)
1954
45
46
47
48
49
50

Variations for Retinitis Pigmentosa

About this section

UniProtKB/Swiss-Prot genetic disease variations for Retinitis Pigmentosa:

67
id Symbol AA change Variation ID SNP ID
1CRXp.Arg41GlnVAR_007946
2CRXp.Gly122AspVAR_008282rs61748441

Clinvar genetic disease variations for Retinitis Pigmentosa:

5 (show all 105)
id Gene Variation Type Significance SNP ID Assembly Location
1RHONM_000539.3(RHO): c.403C> T (p.Arg135Trp)single nucleotide variantPathogenicrs104893775GRCh37Chr 3, 129249760: 129249760
2RHONM_000539.3(RHO): c.44A> G (p.Asn15Ser)single nucleotide variantPathogenicrs104893786GRCh37Chr 3, 129247620: 129247620
3PDE6BNM_000283.3(PDE6B): c.1669C> T (p.His557Tyr)single nucleotide variantPathogenicrs121918581GRCh37Chr 4, 655977: 655977
4RPE65NM_000329.2(RPE65): c.1543C> T (p.Arg515Trp)single nucleotide variantPathogenicrs121917745GRCh37Chr 1, 68895518: 68895518
5MYO7ANM_000260.3(MYO7A): c.1667G> T (p.Gly556Val)single nucleotide variantLikely pathogenicrs527236085GRCh38Chr 11, 77162965: 77162965
6PDE6BNM_000283.3(PDE6B): c.1467+1G> Csingle nucleotide variantPathogenicrs527236089GRCh37Chr 4, 652807: 652807
7PDE6BNM_000283.3(PDE6B): c.1576G> A (p.Glu526Lys)single nucleotide variantLikely pathogenicrs527236091GRCh37Chr 4, 654364: 654364
8PDE6BNM_000283.3(PDE6B): c.1604T> A (p.Ile535Asn)single nucleotide variantPathogenicrs527236088GRCh37Chr 4, 654392: 654392
9PDE6BNM_000283.3(PDE6B): c.993-1G> Csingle nucleotide variantLikely pathogenicrs527236090GRCh37Chr 4, 649728: 649728
10PRPH2NM_000322.4(PRPH2): c.410G> A (p.Gly137Asp)single nucleotide variantPathogenicrs527236097GRCh37Chr 6, 42689663: 42689663
11PRPH2NM_000322.4(PRPH2): c.499G> A (p.Gly167Ser)single nucleotide variantPathogenicrs527236098GRCh37Chr 6, 42689574: 42689574
12ROM1NM_000327.3(ROM1): c.331dupG (p.Leu114Alafs)duplicationPathogenicrs527236104GRCh38Chr 11, 62613612: 62613612
13RHONM_000539.3(RHO): c.180C> A (p.Tyr60Ter)single nucleotide variantLikely pathogenicrs527236101GRCh37Chr 3, 129247756: 129247756
14RHONM_000539.3(RHO): c.520G> A (p.Gly174Ser)single nucleotide variantPathogenicrs527236103GRCh37Chr 3, 129249877: 129249877
15RHONM_000539.3(RHO): c.562G> A (p.Gly188Arg)single nucleotide variantPathogenicrs527236100GRCh37Chr 3, 129251125: 129251125
16RHONM_000539.3(RHO): c.977_980delACCC (p.Pro327Trpfs)deletionLikely pathogenicrs527236102GRCh37Chr 3, 129252491: 129252494
17CRXNM_000554.4(CRX): c.193G> C (p.Asp65His)single nucleotide variantPathogenicrs527236062GRCh38Chr 19, 47836335: 47836335
18CRXNM_000554.4(CRX): c.897G> C (p.Leu299Phe)single nucleotide variantLikely pathogenicrs527236063GRCh38Chr 19, 47839964: 47839964
19C2orf71NM_001029883.2(C2orf71): c.2126delG (p.Gly709Glufs)deletionLikely pathogenicrs527236055GRCh37Chr 2, 29295002: 29295002
20C2orf71NM_001029883.2(C2orf71): c.2988dupC (p.Thr997Hisfs)duplicationLikely pathogenicrs527236056GRCh37Chr 2, 29294140: 29294140
21RPGRNM_001034853.1(RPGR): c.1087_1088insGTAG (p.Val363Glyfs)insertionLikely pathogenicrs527236109GRCh37Chr X, 38158366: 38158367
22RPGRNM_001034853.1(RPGR): c.1981G> T (p.Glu661Ter)single nucleotide variantLikely pathogenicrs527236108GRCh37Chr X, 38146271: 38146271
23RPGRNM_000328.2(RPGR): c.894_895delTT (p.Ser298Argfs)deletionLikely pathogenicrs527236111GRCh37Chr X, 38163927: 38163928
24RPGRNM_001034853.1(RPGR): c.922G> C (p.Ala308Pro)single nucleotide variantLikely pathogenicrs527236112GRCh37Chr X, 38163900: 38163900
25NM_001077620.2(PRCD): c.2T> C (p.Met1Thr)single nucleotide variantPathogenicrs527236092GRCh37Chr 17, 74536225: 74536225
26NM_001142564.1(CNGA1): c.1046G> A (p.Arg349His)single nucleotide variantLikely pathogenicrs375412499GRCh37Chr 4, 47939672: 47939672
27NM_001142564.1(CNGA1): c.1196A> G (p.Asp399Gly)single nucleotide variantLikely pathogenicrs527236059GRCh37Chr 4, 47939522: 47939522
28NM_001142564.1(CNGA1): c.1840G> A (p.Gly614Ser)single nucleotide variantLikely pathogenicrs527236057GRCh37Chr 4, 47938878: 47938878
29NM_001142564.1(CNGA1): c.398delG (p.Gly133Valfs)deletionLikely pathogenicrs527236058GRCh37Chr 4, 47953415: 47953415
30EYSNM_001142800.1(EYS): c.1345A> T (p.Lys449Ter)single nucleotide variantLikely pathogenicrs527236077GRCh37Chr 6, 66063465: 66063465
31EYSNM_001142800.1(EYS): c.1750G> T (p.Glu584Ter)single nucleotide variantLikely pathogenicrs527236072GRCh37Chr 6, 66044889: 66044889
32EYSNM_001142800.1(EYS): c.4387delA (p.Arg1463Glyfs)deletionLikely pathogenicrs527236075GRCh37Chr 6, 65301373: 65301373
33EYSNM_001142800.1(EYS): c.4402_4403insTCAAGAGG (p.Asp1468Valfs)insertionLikely pathogenicrs527236073GRCh37Chr 6, 65301357: 65301358
34EYSNM_001142800.1(EYS): c.4957dupA (p.Ser1653Lysfs)duplicationPathogenicrs527236065GRCh38Chr 6, 64590910: 64590910
35EYSNM_001142800.1(EYS): c.5014C> T (p.Gln1672Ter)single nucleotide variantLikely pathogenicrs527236074GRCh37Chr 6, 65300746: 65300746
36EYSNM_001142800.1(EYS): c.5202_5203delGT (p.Phe1735Glnfs)deletionLikely pathogenicrs527236071GRCh37Chr 6, 65300557: 65300558
37EYSNM_001142800.1(EYS): c.6557G> A (p.Gly2186Glu)single nucleotide variantPathogenicrs527236068GRCh37Chr 6, 64791763: 64791763
38EYSNM_001142800.1(EYS): c.7048delT (p.Cys2350Alafs)deletionLikely pathogenicrs527236069GRCh37Chr 6, 64694283: 64694283
39EYSNM_001142800.1(EYS): c.7694delA (p.Asn2565Metfs)deletionLikely pathogenicrs527236078GRCh37Chr 6, 64498027: 64498027
40EYSNM_001142800.1(EYS): c.7793G> A (p.Gly2598Asp)single nucleotide variantPathogenicrs527236064GRCh37Chr 6, 64488004: 64488004
41EYSNM_001142800.1(EYS): c.7919G> A (p.Trp2640Ter)single nucleotide variantPathogenicrs527236066GRCh37Chr 6, 64472506: 64472506
42EYSNM_001142800.1(EYS): c.8012T> A (p.Leu2671Ter)single nucleotide variantLikely pathogenicrs527236076GRCh37Chr 6, 64472413: 64472413
43EYSNM_001142800.1(EYS): c.8379_8380insTGCA (p.Glu2794Cysfs)insertionLikely pathogenicrs527236070GRCh37Chr 6, 64431547: 64431548
44EYSNM_001142800.1(EYS): c.8805C> A (p.Tyr2935Ter)single nucleotide variantPathogenicrs527236067GRCh37Chr 6, 64431122: 64431122
45EYSNM_001142800.1(EYS): c.9209T> C (p.Ile3070Thr)single nucleotide variantPathogenicrs183589498GRCh37Chr 6, 64430718: 64430718
46MAKNM_001242385.1(MAK): c.340dupG (p.Ala114Glyfs)duplicationLikely pathogenicrs527236082GRCh37Chr 6, 10813895: 10813895
47MAKNM_001242385.1(MAK): c.496C> T (p.Arg166Cys)single nucleotide variantLikely pathogenicrs527236081GRCh37Chr 6, 10804120: 10804120
48MAKNM_001242385.1(MAK): c.553G> A (p.Ala185Thr)single nucleotide variantLikely pathogenicrs527236080GRCh37Chr 6, 10804063: 10804063
49CNGB1NM_001297.4(CNGB1): c.217+5G> Csingle nucleotide variantLikely pathogenicrs527236060GRCh38Chr 16, 57964482: 57964482
50CNGB1NM_001297.4(CNGB1): c.2524dupA (p.Thr842Asnfs)duplicationLikely pathogenicrs527236061GRCh38Chr 16, 57904844: 57904844
51TULP1NM_003322.4(TULP1): c.349G> A (p.Glu117Lys)single nucleotide variantLikely pathogenicrs527236117GRCh37Chr 6, 35479425: 35479425
52BEST1NM_004183.3(BEST1): c.763C> T (p.Arg255Trp)single nucleotide variantPathogenicrs372989281GRCh38Chr 11, 61958194: 61958194
53LRATNM_004744.4(LRAT): c.163C> T (p.Arg55Trp)single nucleotide variantLikely pathogenicrs527236079GRCh37Chr 4, 155665641: 155665641
54TOPORSNM_005802.4(TOPORS): c.2554_2557delGAGA (p.Glu852Glnfs)deletionPathogenicrs527236116GRCh37Chr 9, 32541966: 32541969
55NRLNM_006177.3(NRL): c.23delT (p.Leu8Argfs)deletionLikely pathogenicrs527236087GRCh37Chr 14, 24552035: 24552035
56RP1NM_006269.1(RP1): c.1186C> T (p.Arg396Ter)single nucleotide variantLikely pathogenicrs201493928GRCh37Chr 8, 55537628: 55537628
57RP1NM_006269.1(RP1): c.4876G> A (p.Gly1626Arg)single nucleotide variantLikely pathogenicrs527236106GRCh37Chr 8, 55541318: 55541318
58RP1NM_006269.1(RP1): c.5797C> T (p.Arg1933Ter)single nucleotide variantLikely pathogenicrs118031911GRCh37Chr 8, 55542239: 55542239
59RP1NM_006269.1(RP1): c.649delG (p.Gly217Glufs)deletionLikely pathogenicrs527236105GRCh37Chr 8, 55534710: 55534710
60MERTKNM_006343.2(MERTK): c.1450G> A (p.Gly484Ser)single nucleotide variantLikely pathogenicrs527236084GRCh37Chr 2, 112751981: 112751981
61MERTKNM_006343.2(MERTK): c.225delA (p.Gly76Glufs)deletionLikely pathogenicrs527236083GRCh37Chr 2, 112686860: 112686860
62PRPF6NM_012469.3(PRPF6): c.550G> C (p.Asp184His)single nucleotide variantLikely pathogenicrs527236096GRCh37Chr 20, 62626380: 62626380
63SNRNP200NM_014014.4(SNRNP200): c.1871G> A (p.Arg624Lys)single nucleotide variantLikely pathogenicrs527236115GRCh37Chr 2, 96959219: 96959219
64SNRNP200NM_014014.4(SNRNP200): c.2042G> A (p.Arg681His)single nucleotide variantPathogenicrs527236113GRCh37Chr 2, 96958828: 96958828
65SNRNP200NM_014014.4(SNRNP200): c.2047G> T (p.Val683Leu)single nucleotide variantPathogenicrs527236114GRCh37Chr 2, 96958823: 96958823
66NR2E3NM_014249.3(NR2E3): c.364C> T (p.Arg122Cys)single nucleotide variantLikely pathogenicrs527236086GRCh38Chr 15, 71811969: 71811969
67PRPF31NM_015629.3(PRPF31): c.562G> T (p.Glu188Ter)single nucleotide variantLikely pathogenicrs527236094GRCh38Chr 19, 54123783: 54123783
68PRPF31NM_015629.3(PRPF31): c.615C> G (p.Tyr205Ter)single nucleotide variantLikely pathogenicrs144738703GRCh38Chr 19, 54123836: 54123836
69PRPF31NM_015629.3(PRPF31): c.764A> T (p.Gln255Leu)single nucleotide variantLikely pathogenicrs527236095GRCh38Chr 19, 54124565: 54124565
70IMPG2NM_016247.3(IMPG2): c.3262C> T (p.Arg1088Ter)single nucleotide variantPathogenicrs199867882GRCh37Chr 3, 100949961: 100949961
71RDH12NM_152443.2(RDH12): c.776delG (p.Glu260Argfs)deletionPathogenicrs527236099GRCh37Chr 14, 68196025: 68196025
72RP1L1NM_178857.5(RP1L1): c.1972C> T (p.Arg658Ter)single nucleotide variantLikely pathogenicrs527236107GRCh37Chr 8, 10469636: 10469636
73RP1L1NM_178857.5(RP1L1): c.235C> T (p.Arg79Cys)single nucleotide variantLikely pathogenicrs377269054GRCh37Chr 8, 10480477: 10480477
74USH2ANM_206933.2(USH2A): c.10544A> G (p.Asp3515Gly)single nucleotide variantPathogenicrs527236119GRCh37Chr 1, 215956121: 215956121
75USH2ANM_206933.2(USH2A): c.13466G> A (p.Gly4489Asp)single nucleotide variantLikely pathogenicrs527236127GRCh37Chr 1, 215847787: 215847787
76USH2ANM_206933.2(USH2A): c.13847G> T (p.Gly4616Val)single nucleotide variantLikely pathogenicrs527236124GRCh37Chr 1, 215844600: 215844600
77USH2ANM_206933.2(USH2A): c.14243C> T (p.Ser4748Phe)single nucleotide variantLikely pathogenicrs527236126GRCh38Chr 1, 215650692: 215650692
78USH2ANM_206933.2(USH2A): c.14450G> A (p.Gly4817Glu)single nucleotide variantLikely pathogenicrs527236125GRCh37Chr 1, 215822002: 215822002
79USH2ANM_206933.2(USH2A): c.15233C> G (p.Pro5078Arg)single nucleotide variantPathogenicrs527236122GRCh37Chr 1, 215807865: 215807865
80USH2ANM_206933.2(USH2A): c.1722_1723insGA (p.Cys575Aspfs)insertionLikely pathogenicrs527236121GRCh37Chr 1, 216465634: 216465635
81USH2ANM_206933.2(USH2A): c.2802T> G (p.Cys934Trp)single nucleotide variantPathogenicrs201527662GRCh37Chr 1, 216419934: 216419934
82USH2ANM_206933.2(USH2A): c.490G> T (p.Val164Phe)single nucleotide variantLikely pathogenicrs527236123GRCh37Chr 1, 216592017: 216592017
83USH2ANM_206933.2(USH2A): c.6399G> A (p.Trp2133Ter)single nucleotide variantLikely pathogenicrs55958016GRCh37Chr 1, 216173831: 216173831
84USH2ANM_206933.2(USH2A): c.8682delG (p.Arg2894Serfs)deletionLikely pathogenicrs527236120GRCh37Chr 1, 216040512: 216040512
85USH2ANM_206933.2(USH2A): c.9751T> C (p.Cys3251Arg)single nucleotide variantPathogenicrs527236118GRCh37Chr 1, 215972456: 215972456
86RPGRNM_001034853.1(RPGR): c.2426_2427delAG (p.Glu809Glyfs)deletionPathogenicrs730882261GRCh37Chr X, 38145825: 38145826
87ABCA4NM_000350.2(ABCA4): c.2927delT (p.Leu976Argfs)deletionPathogenicrs863223338GRCh38Chr 1, 94044736: 94044736
88PDE6BNM_000283.3(PDE6B): c.1060-1G> Tsingle nucleotide variantPathogenicrs863223339GRCh37Chr 4, 650033: 650033
89RP1NM_006269.1(RP1): c.679T> G (p.Phe227Val)single nucleotide variantPathogenicrs863223340GRCh37Chr 8, 55534740: 55534740
90IFT140NM_014714.3(IFT140): c.3827G> A (p.Gly1276Glu)single nucleotide variantPathogenicrs779007169GRCh38Chr 16, 1520177: 1520177
91CRB1NM_001257965.1(CRB1): c.2711G> A (p.Cys904Tyr)single nucleotide variantPathogenicrs863223341GRCh37Chr 1, 197398685: 197398685
92CRB1NM_001257965.1(CRB1): c.1252dupT (p.Ser418Phefs)duplicationPathogenicrs863223342GRCh38Chr 1, 197421287: 197421287
93PANK2NM_024960.4(PANK2): c.419T> C (p.Phe140Ser)single nucleotide variantPathogenicrs863223343GRCh38Chr 20, 3912514: 3912514
94C2orf71NM_001029883.2(C2orf71): c.712A> T (p.Lys238Ter)single nucleotide variantPathogenicrs863223344GRCh37Chr 2, 29296416: 29296416
95RDH12NM_152443.2(RDH12): c.377C> T (p.Ala126Val)single nucleotide variantPathogenicrs202126574GRCh37Chr 14, 68192801: 68192801
96USH2ANM_206933.2(USH2A): c.2299delG (p.Glu767Serfs)deletionPathogenicrs80338903GRCh37Chr 1, 216420437: 216420437
97USH2ANM_206933.2(USH2A): c.2276G> T (p.Cys759Phe)single nucleotide variantLikely pathogenic, Pathogenicrs80338902GRCh37Chr 1, 216420460: 216420460
98USH2ANM_206933.2(USH2A): c.14020A> G (p.Arg4674Gly)single nucleotide variantPathogenicrs80338904GRCh37Chr 1, 215844427: 215844427
99USH2ANM_206933.2(USH2A): c.8559-2A> Gsingle nucleotide variantPathogenicrs397518039GRCh37Chr 1, 216051224: 216051224
100UNC119NM_005148.3(UNC119): c.169A> T (p.Lys57Ter)single nucleotide variantPathogenicrs267607166GRCh37Chr 17, 26879407: 26879407
101RP1NM_006269.1(RP1): c.1118C> T (p.Thr373Ile)single nucleotide variantPathogenicrs77775126GRCh37Chr 8, 55537560: 55537560
102TULP1NM_003322.4(TULP1): c.1145T> C (p.Phe382Ser)single nucleotide variantPathogenicrs121909076GRCh37Chr 6, 35471593: 35471593
103PRPH2NM_000322.4(PRPH2): c.736T> C (p.Trp246Arg)single nucleotide variantPathogenicrs61755817GRCh37Chr 6, 42672195: 42672195
104RPGRNM_000328.2(RPGR): c.469+1G> Asingle nucleotide variantLikely pathogenicrs62638646GRCh37Chr X, 38178081: 38178081
105RPE65NM_000329.2(RPE65): c.118G> A (p.Gly40Ser)single nucleotide variantPathogenicrs61751281GRCh37Chr 1, 68912520: 68912520

Expression for genes affiliated with Retinitis Pigmentosa

About this section
Search GEO for disease gene expression data for Retinitis Pigmentosa.

Pathways for genes affiliated with Retinitis Pigmentosa

About this section

GO Terms for genes affiliated with Retinitis Pigmentosa

About this section

Cellular components related to Retinitis Pigmentosa according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Golgi apparatusGO:000579410.6RHO, RPGR

Biological processes related to Retinitis Pigmentosa according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1photoreceptor cell maintenanceGO:004549411.0RHO, TULP1
2retina morphogenesis in camera-type eyeGO:006004211.0ROM1, RPE65
3response to light stimulusGO:000941610.9RHO, RPE65
4retina development in camera-type eyeGO:006004110.9IFT140, PDE6B, RP1, RPE65
5visual perceptionGO:000760110.8C2orf71, PRPH2, RDH12, RPE65
6phototransduction, visible lightGO:000760310.5PDE6B, RDH12, RHO, RP1

Sources for Retinitis Pigmentosa

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet